183 related articles for article (PubMed ID: 30779036)
21. [Malignant lymphomas - quo vadis? - What developments await us in diagnostics and therapy?].
Alig S; Pott C; Chapuy B
Dtsch Med Wochenschr; 2024 May; 149(11):638-645. PubMed ID: 38749440
[TBL] [Abstract][Full Text] [Related]
22. PrecisionLymphoNet: Advancing Malignant Lymphoma Diagnosis via Ensemble Transfer Learning with CNNs.
Rajadurai S; Perumal K; Ijaz MF; Chowdhary CL
Diagnostics (Basel); 2024 Feb; 14(5):. PubMed ID: 38472941
[TBL] [Abstract][Full Text] [Related]
23. B-cell non-Hodgkin lymphomas.
Silkenstedt E; Salles G; Campo E; Dreyling M
Lancet; 2024 May; 403(10438):1791-1807. PubMed ID: 38614113
[TBL] [Abstract][Full Text] [Related]
24. Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era?
Gritti G; Pavoni C; Rambaldi A
Mediterr J Hematol Infect Dis; 2017; 9(1):e2017010. PubMed ID: 28101314
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in understanding the biology of follicular lymphoma.
Nishikori M
Int J Hematol; 2024 Mar; ():. PubMed ID: 38536645
[TBL] [Abstract][Full Text] [Related]
26. Advancements in minimal residual disease detection: a practical approach using single-cell droplet PCR for comprehensive monitoring in hematological malignancy.
Uchiyama S; Fukushima K; Katagiri S; Tsuchiya J; Kubo T; Chi S; Minami Y
Ther Adv Hematol; 2024; 15():20406207241245510. PubMed ID: 38628436
[TBL] [Abstract][Full Text] [Related]
27. The gray area of RQ-PCR-based measurable residual disease: subdividing the "positive, below quantitative range" category.
Kotrova M; Fronkova E; Svaton M; Drandi D; Schön F; Hoogeveen P; Hancock J; Skotnicova A; Schilhabel A; Eckert C; Clappier E; Cazzaniga G; Schäfer BW; van Dongen JJM; Ritgen M; Pott C; van der Velden VHJ; Trka J; Brüggemann M
Leukemia; 2024 May; ():. PubMed ID: 38760480
[No Abstract] [Full Text] [Related]
28. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
Pott C; Sehn LH; Belada D; Gribben J; Hoster E; Kahl B; Kehden B; Nicolas-Virelizier E; Spielewoy N; Fingerle-Rowson G; Harbron C; Mundt K; Wassner-Fritsch E; Cheson BD
Leukemia; 2020 Feb; 34(2):522-532. PubMed ID: 31462735
[TBL] [Abstract][Full Text] [Related]
29. Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network.
Drandi D; Alcantara M; Benmaad I; Söhlbrandt A; Lhermitte L; Zaccaria G; Ferrante M; Genuardi E; Mantoan B; Villarese P; Cheminant M; Starza ID; Ciabatti E; Bomben R; Jimenez C; Callanan M; Abdo C; Eckert C; Ribrag V; Cortelazzo S; Dreyling M; Hermine O; Delfau-Larue MH; Pott C; Ladetto M; Ferrero S; Macintyre E
Hemasphere; 2020 Apr; 4(2):e347. PubMed ID: 32309784
[TBL] [Abstract][Full Text] [Related]
30. The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice.
Galimberti S; Genuardi E; Mazziotta F; Iovino L; Morabito F; Grassi S; Ciabatti E; Guerrini F; Petrini M
Front Oncol; 2019; 9():528. PubMed ID: 31293969
[TBL] [Abstract][Full Text] [Related]
31. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
[TBL] [Abstract][Full Text] [Related]
32. Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance.
Ladetto M; Tavarozzi R; Pott C
Hematol Oncol Clin North Am; 2020 Oct; 34(5):887-901. PubMed ID: 32861285
[TBL] [Abstract][Full Text] [Related]
33. Mantle cell lymphoma.
Cortelazzo S; Ponzoni M; Ferreri AJM; Dreyling M
Crit Rev Oncol Hematol; 2020 Sep; 153():103038. PubMed ID: 32739830
[TBL] [Abstract][Full Text] [Related]
34. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
Cirillo M; Craig AFM; Borchmann S; Kurtz DM
Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study.
Delfau-Larue MH; Boulland ML; Beldi-Ferchiou A; Feugier P; Maisonneuve H; Casasnovas RO; Lemonnier F; Pica GM; Houot R; Ysebaert L; Tilly H; Eisenmann JC; Le Gouill S; Ribrag V; Godmer P; Glaisner S; Cartron G; Xerri L; Salles GA; Fest T; Morschhauser F
Blood Adv; 2020 Aug; 4(14):3217-3223. PubMed ID: 32673385
[TBL] [Abstract][Full Text] [Related]
36. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Del Giudice I; Raponi S; Della Starza I; De Propris MS; Cavalli M; De Novi LA; Cappelli LV; Ilari C; Cafforio L; Guarini A; Foà R
Front Oncol; 2019; 9():689. PubMed ID: 31555576
[TBL] [Abstract][Full Text] [Related]
37. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.
Della Starza I; Chiaretti S; De Propris MS; Elia L; Cavalli M; De Novi LA; Soscia R; Messina M; Vitale A; Guarini A; Foà R
Front Oncol; 2019; 9():726. PubMed ID: 31448230
[No Abstract] [Full Text] [Related]
38. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
Della Starza I; Cavalli M; De Novi LA; Genuardi E; Mantoan B; Drandi D; Barbero D; Ciabatti E; Grassi S; Gazzola A; Mannu C; Agostinelli C; Piccaluga PP; Bomben R; Degan M; Gattei V; Guarini A; Foà R; Galimberti S; Ladetto M; Ferrero S; Del Giudice I;
Hematol Oncol; 2019 Oct; 37(4):368-374. PubMed ID: 31325190
[TBL] [Abstract][Full Text] [Related]
39. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS.
Scheijen B; Meijers RWJ; Rijntjes J; van der Klift MY; Möbs M; Steinhilber J; Reigl T; van den Brand M; Kotrová M; Ritter JM; Catherwood MA; Stamatopoulos K; Brüggemann M; Davi F; Darzentas N; Pott C; Fend F; Hummel M; Langerak AW; Groenen PJTA;
Leukemia; 2019 Sep; 33(9):2227-2240. PubMed ID: 31197258
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
